SMART Protocol vs Antagonist Protocol in IVF
Launched by CLINIQUE OVO · Dec 22, 2022
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
A limited number of studies suggest that the addition of letrozole to gonadotropins for IVF is associated with an increase in oocyte count, blastocyst count and implantation rate. These differences are presumed to be caused by an increase in intra-ovarian androgens associated with the addition of letrozole.
In patients with reduced ovarian reserve or reduced oocyte quality in the previous cycle, supplementation with of letrozole has the potential to increase oocyte count or oocyte quality, thereby resulting in more transferable blastocysts. The antagonist stimulation protocol with the addi...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria for the SMART IVF protocol:
- • Women between the ages of 20 and 42 inclusively
- • Women proceeding with a SMART IVF protocol following an antagonist IVF protocol between 2010 and 2020 (study group) or women proceeding with an antagonist protocol following an antagonist IVF protocol between 2010 and 2020 (control group)
- • Delay of 1 year between both IVF cycle
- Exclusion Criteria:
- • Women undergoing fertility preservation
- • Oocyte donation IVF cycles
- • Diagnosed severe male factor requiring surgical sperm extraction (micro-tese or TESA)
About Clinique Ovo
Clinique OVO is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative research and development. Focused on enhancing patient outcomes, the organization specializes in conducting rigorous clinical trials across various therapeutic areas, including dermatology, oncology, and chronic disease management. With a commitment to ethical practices and patient safety, Clinique OVO collaborates with healthcare professionals and regulatory bodies to ensure the highest standards of scientific integrity and compliance. By leveraging cutting-edge methodologies and technologies, Clinique OVO aims to contribute to the discovery of novel treatments and improve the quality of life for patients globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Robert Hemmings, MD
Principal Investigator
Clinique Ovo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials